Vascular effects of statins in stroke

• Published in: Stroke (1970) 1997-11, Vol.28 (11), p.2315-2320
• Main Authors: DELANTY, N, VAUGHAN, C. J
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Blood Vessels - drug effects; Cerebrovascular Disorders - drug therapy; Clinical Trials as Topic; General and cellular metabolism. Vitamins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Medical sciences; Pharmacology. Drug treatments
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/01.str.28.11.2315

Recent clinical trials and meta-analyses of beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have demonstrated a reduction in ischemic stroke in patients with a history of coronary artery disease both with and without elevations of serum cholesterol. This review summarizes clinical trials of these compounds and their recent impact on stroke and explores the underlying vascular mechanisms of their actions. Use of statins in patients with vascular disease has been shown to lower the incidence of stroke by approximately 30%. Statins exhibit a number of antiatherosclerotic and antithrombotic properties that likely underlie the recently observed reductions in cerebrovascular disease. Statins reduce inflammatory, proliferative, and thrombogenic processes in plaque, making it less likely to rupture. Additionally, they reverse the endothelial dysfunction and platelet activation accompanying hypercholesterolemia and may reduce the tendency to thrombosis. Hypercholesterolemia has reemerged as a risk factor for ischemic stroke. Statins protect against thromboembolic stroke through multiple beneficial effects within the vascular milieu. Further data are awaited to support the growing importance of cholesterol as a risk factor for ischemic stroke and the benefits of statin therapy in patients with cerebrovascular disease.